Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.
about
Role of stromal cell-derived factor 1α pathway in bone metastatic prostate cancerCombination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamicsTargeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcomaModulation of Host Angiogenesis as a Microbial Survival Strategy and Therapeutic TargetOvercoming Hypoxia-Mediated Tumor Progression: Combinatorial Approaches Targeting pH Regulation, Angiogenesis and Immune DysfunctionThe progress of angiogenic factors in the development of leukemiasRemodeling Components of the Tumor Microenvironment to Enhance Cancer TherapyThe Contribution of Angiogenesis to the Process of MetastasisCompensatory angiogenesis and tumor refractorinessA phosphodiesterase 4B-dependent interplay between tumor cells and the microenvironment regulates angiogenesis in B-cell lymphoma.Glycolytic regulation of cell rearrangement in angiogenesis.Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies.Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancerMicroenvironmental Targets in SarcomaHypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to HypoxiaProdrug AST-003 Improves the Therapeutic Index of the Multi-Targeted Tyrosine Kinase Inhibitor SunitinibMacrophages: An Inflammatory Link Between Angiogenesis and Lymphangiogenesis.Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular SchwannomasQuantification of Microvascular Tortuosity during Tumor Evolution Using Acoustic AngiographyAnti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma modelNCI-60 Cell Line Screening: A Radical Departure in its Time.Radiation treatment monitoring using multimodal functional imaging: PET/CT ((18)F-Fluoromisonidazole & (18)F-Fluorocholine) and DCE-US.(18)F-fluoromisonidazole kinetic modeling for characterization of tumor perfusion and hypoxia in response to antiangiogenic therapy.Model driven optimization of antiangiogenics + cytotoxics combination: application to breast cancer mice treated with bevacizumab + paclitaxel doublet leads to reduced tumor growth and fewer metastasisThe "inherent vice" in the anti-angiogenic theory may cause the highly metastatic cancer to spread more aggressively.Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated 18F-Fluorodeoxyglucose (18F-FDG) positron emission tomography/magnetic resonance imaging (PET/MRI); The REMAP studyImproved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.Emerging strategies for treating brain metastases from breast cancer.Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery.CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in miceSmall-molecule BH3 mimetic and pan-Bcl-2 inhibitor AT-101 enhances the antitumor efficacy of cisplatin through inhibition of APE1 repair and redox activity in non-small-cell lung cancer.Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis modelAnti-Angiogenic Properties of BDDPM, a Bromophenol from Marine Red Alga Rhodomela confervoides, with Multi Receptor Tyrosine Kinase Inhibition Effects.Combined Use of Oligopeptides, Fragment Libraries, and Natural Compounds: A Comprehensive Approach To Sample the Druggability of Vascular Endothelial Growth Factor.Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.Preclinical Testing Oncolytic Vaccinia Virus Strain GLV-5b451 Expressing an Anti-VEGF Single-Chain Antibody for Canine Cancer Therapy.Therapy: Lenvatinib and radioiodine-refractory thyroid cancers.The role of photodynamic therapy in overcoming cancer drug resistance.Functional expression of sodium-glucose transporters in cancer.Modulation of the tumor vasculature and oxygenation to improve therapy
P2860
Q26741064-25748976-D36A-4F64-A9C3-726946708BF8Q26746067-307E2A26-6E2D-4AE7-BA3C-7197EA55A2CAQ26747666-9CE0253C-79AD-42D1-A1B2-894817A67D35Q26748251-DE67BE66-CBD3-42B5-8FB2-DD95628AD4C6Q26749333-AF9BAD0A-B8B4-413A-B41F-61F37447B9A2Q26753835-F265DE25-602C-4C51-A20F-E0E97051E603Q26777144-5AFD9F0D-7C4D-41CA-81D7-FA8C2581F092Q26801841-F0870229-90A5-4714-8AFB-66711DA98BEFQ26851916-54827F83-4506-468C-A7BC-43B280FDE559Q27320446-97ABCA48-3C08-48CD-AB36-47E915FE5925Q27335102-29140600-827C-4A08-BB43-4F40A02AC81CQ27853358-72FD9DE4-1099-4FCA-B1F5-25760D9093B1Q28068654-B9AA033E-CD59-48B2-A39A-AA8E7A7567BDQ28081400-52165130-BAF0-4AD0-AB34-CD9DC4040F5AQ28085029-1A64E436-CC74-4E13-B401-CBF18D378229Q28550556-EDE22F11-4013-468E-A223-971B25A2E769Q30278005-425258E0-674E-44AB-BE73-5F08348EB557Q30359059-433B9B8A-8DC6-4EAA-A8CA-090A84E9BF4BQ30380570-18AE172B-26EA-45B3-B91B-0CE846759F5AQ30383248-6E971376-90A1-438D-B85D-14F3C6643D7EQ30383428-D6401D6D-8CDD-4E85-87A8-86483F5BAC86Q30395717-57BCCCBB-DF03-4200-BF26-0C6E464A73DEQ32179417-596E50FB-E96B-4B63-A185-8747EDE4D215Q33618582-482292A8-0153-4926-BC24-878A56DCAE6BQ33725650-E0025334-D1B2-42FC-92A1-68561D36A327Q33755947-636F4007-0E57-4CCF-B2E9-E26557E1F1AFQ35062862-561EBD03-8D61-4A15-A997-5703F0C2B63FQ35075446-9387705C-6AE3-492E-9398-544234C64CBCQ35090116-D7E1FE0D-7E61-4E4A-89F5-C0F4AEE54AF7Q35528287-5A78BCA1-BC6F-4794-82DD-ABA8B71DA0D0Q35743521-9DEF3848-E43E-4DD1-BC39-1FA490DF3EA6Q35777174-FB259B4E-3594-4E6A-8C91-52D401068C2FQ35814050-10C6CD99-DC0E-4B49-B2A3-14EA95349C4EQ35836815-6F7635B7-E9D3-4661-9750-02103466E340Q35895174-88651972-317F-407D-BEAA-8A6FAA17BF32Q35895339-2F396FBE-C35A-45A7-BB71-D5688F561394Q35899921-C65AB464-CAEA-4C5D-8AEA-DE9284FF6869Q35904547-0F1F02CD-7117-4124-8EC4-EC1330AFEDB9Q35909986-0D7C4D3F-1577-4018-9F16-1D1946190702Q35920685-5650CDBE-A1E6-40A8-A0BE-A69CB3AFB1ED
P2860
Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.
@ast
Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.
@en
type
label
Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.
@ast
Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.
@en
prefLabel
Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.
@ast
Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.
@en
P2860
P1433
P1476
Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.
@en
P2093
Rakesh K Jain
P2860
P304
P356
10.1016/J.CCELL.2014.10.006
P577
2014-11-10T00:00:00Z